Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases

Cancer Letters, 05/11/2012

Radium–223 is the first agent in this class to show an overall survival advantage in CRPC patients with bone metastases. This landmark finding will likely have a considerable impact on the treatment paradigm of bone–metastatic castration–resistant prostate cancer (CRPC), and will pave the way for further developments in the future.

Print Article Summary Cat 2 CME Report